Kobayashi Pharmaceutical Co., Ltd.
KBYPFOTCConsumer Defensive● Active
$34.05
+$0.00(+0.00%)
Market Cap$2.5B
P/E Ratio—
52W High$37.43
52W Low$34.05
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KBYPF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $165.89B | $165.60B | $173.46B | $166.26B | $155.25B |
| Cost of Revenue | $86.38B | $78.00B | $77.08B | $73.93B | $66.48B |
| Gross Profit | $79.51B | $87.60B | $96.38B | $92.33B | $88.77B |
| Gross Margin %(computed) | 47.93% | 52.90% | 55.56% | 55.53% | 57.18% |
| Operating Expenses | |||||
| R&D Expenses | $9.13B | $9.11B | $9.00B | $8.33B | $7.52B |
| G&A Expenses | $0.00B | $5.16B | $29.87B | $5.02B | $5.20B |
| Total Operating Expenses | $64.65B | $62.74B | $70.60B | $65.66B | $62.70B |
| Operating Income | $14.86B | $24.86B | $25.78B | $26.67B | $26.07B |
| Operating Margin %(computed) | 8.96% | 15.01% | 14.86% | 16.04% | 16.79% |
| Interest Income | $0.34B | $0.21B | $0.21B | $0.09B | $0.13B |
| Interest Expense | $0.03B | $0.03B | $0.03B | $0.02B | $0.02B |
| Income Before Tax | $3.75B | $13.91B | $27.56B | $27.95B | $27.64B |
| Income Tax Expense | $0.08B | $3.84B | $7.22B | $7.93B | $7.92B |
| Net Income | $3.66B | $10.07B | $20.34B | $20.02B | $19.71B |
| Net Margin %(computed) | 2.21% | 6.08% | 11.73% | 12.04% | 12.70% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $48.62 | $135.42 | $268.16 | $259.63 | $252.36 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.08B | 0.08B | 0.08B |
| EBITDA | $23.61B | $21.96B | $33.65B | $31.86B | $30.79B |
| EBITDA Margin %(computed) | 14.23% | 13.26% | 19.40% | 19.17% | 19.83% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · JPY · B
Explore more Kobayashi Pharmaceutical Co., Ltd. data
About Kobayashi Pharmaceutical Co., Ltd. (KBYPF) Income Statement
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KBYPF reported revenue of $165.89B, gross profit of $79.51B (gross margin 47.93%), and net income of $3.66B — a net profit margin of 2.21%.
Frequently asked questions
KBYPF · 4 questionsKobayashi Pharmaceutical Co., Ltd. (KBYPF) reported revenue of $165.89B for 2025, up 0.2% year-over-year.
KBYPF revenueKBYPF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09